Avenue Therapeutics (ATXI) Earnings Date, Estimates & Call Transcripts

$2.12

+0.03 (+1.44%)

(As of 10/16/2024 ET)

Upcoming Earnings Date: Nov. 11Estimated
Actual EPS (Aug. 9): -$6.43 Missed By -$5.38
Consensus EPS (Aug. 9): -$1.05

ATXI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATXI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Behind the Markets

The Standard Oil of AI?

ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...

Click here for the ticker >>>

ATXI Earnings Date and Information

Avenue Therapeutics last released its earnings results on August 9th, 2024. The reported ($6.43) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $5.38. Avenue Therapeutics has generated ($7.88) earnings per share over the last year (($7.88) diluted earnings per share) and currently has a price-to-earnings ratio of 0.1. Avenue Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based off prior year's report dates.

Avenue Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/11/2024 (Estimated)	-	-	-	-	-	-	-
8/9/2024	-	($1.05)	($6.43)	($5.38)	($6.43)	-	-
5/15/2024	Q1 2024	-	($15.40)	($15.40)	($15.40)	-	-
3/18/2024	Q4 2023	-	$42.00	+$42.00	$0.56	-	-
11/13/2023	Q3 2023	-	$4.50	+$4.50	$0.06	-	-
8/10/2023	Q2 2023	-	($39.00)	($39.00)	($0.52)	-	-
5/12/2023	Q1 2023	-	($102.75)	($102.75)	($1.37)	-	-
Election warning coming true… (Ad) If you missed it, my emergency election broadcast is now available - watch it before it's too late. Click here to watch it now.
3/30/2023	Q4 2022	-	$92.25	+$92.25	$1.23	-	-
11/10/2022	Q3 2022	-	($33.75)	($33.75)	($0.45)	-	-
8/15/2022	Q2 2022	-	($33.75)	($33.75)	($0.03)	-	-
5/16/2022	Q1 2022	-	($157.50)	($157.50)	($0.14)	-	-
3/25/2022	Q4 2021	-	($56.25)	($56.25)	($0.75)	-	-
11/15/2021	Q3 2021	-	($56.25)	($56.25)	($0.75)	-	-
8/16/2021	Q2 2021	-	($67.50)	($67.50)	($0.90)	-	-
5/17/2021	Q1 2021	-	($67.50)	($67.50)	($0.90)	-	-
3/31/2021	Q4 2020	-	($67.50)	($67.50)	($0.90)	-	-
11/4/2020	Q3 2020	($112.50)	($67.50)	+$45.00	($0.06)	-	-
8/14/2020	Q2 2020	($123.75)	($123.75)	-	($0.11)	-	-
5/11/2020	Q1 2020	($191.25)	($90.00)	+$101.25	($0.08)	-	-
3/30/2020	Q4 2019	($320.6250)	($370.2623)	($49.6373)	($0.32)	-	-
11/4/2019	Q3 2019	($360.00)	($157.50)	+$202.50	($0.14)	-	-

Avenue Therapeutics Earnings - Frequently Asked Questions

When is Avenue Therapeutics's earnings date?: Avenue Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based off last year's report dates. Learn more on ATXI's earnings history.
Did Avenue Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Avenue Therapeutics (NASDAQ:ATXI) missed the analysts' consensus estimate of ($1.05) by $5.38 with a reported earnings per share (EPS) of ($6.43). Learn more on analysts' earnings estimate vs. ATXI's actual earnings.
How much profit does Avenue Therapeutics generate each year?: Avenue Therapeutics (NASDAQ:ATXI) has a recorded net income of -$10.38 million. ATXI has generated -$7.88 earnings per share over the last four quarters.
What is Avenue Therapeutics's price-to-earnings ratio?: Avenue Therapeutics (NASDAQ:ATXI) has a trailing price-to-earnings ratio of 0.09.